PTGS2 and central nervous system cancer: The magnitudes of fold change of CCL4 (p = 0.004), CSF2 (p = 0.004), CXCL5 (p = 0.007), CXCR2 (p = 0.018), GBP1 (p = 0.014), HLA-C (p = 0.006), IL13 (p = 0.009), NFKB1 (p = 0.005), PTGS2 (p = 0.004), and STAT3 (p = 0.003) genes were observed to be lower in high-grade glioma patients compared to low-grade glioma patients, see Fig. 2b.